Pivotal data are due soon with the Claudin18.2-targeting ADC sonesitatug vedotin.
ApexOnco Front Page
Recent articles
JSKN027 will become the first ADC with this mechanism to enter human trials.
The disappointing Pynnacle trial is set to yield registrational data.
LaNova, which licensed a PD-1 x VEGF to Merck, is acquired by another Chinese player.
MK-8294 starts phase 1, but its mechanism is anybody's guess.
A single but durable stable disease sends the microcap's stock up 730%.
Data on J&J’s Tecvayli and Pfizer’s Elrexfio in relapsed multiple myeloma are due soon.
A newly published cache of CRLs includes six novel oncology drugs.
